Peter Thompson Sells 1,890 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 1,890 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $44.57, for a total value of $84,237.30. Following the transaction, the director directly owned 3,559,765 shares in the company, valued at approximately $158,658,726.05. The trade was a 0.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Sionna Therapeutics Stock Down 14.7%

Shares of NASDAQ SION opened at $35.25 on Friday. The firm’s 50-day moving average price is $41.23 and its 200-day moving average price is $32.82. Sionna Therapeutics, Inc. has a 52-week low of $7.26 and a 52-week high of $45.00. The company has a market cap of $1.57 billion and a PE ratio of -7.24.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06.

More Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Analyst consensus and price targets provide upside context — brokers’ average target (~$45.43) and several buy/strong‑buy reports give the stock valuation support versus current levels, suggesting analysts expect further recovery over time. Read More.
• Neutral Sentiment: Upcoming investor event could be a catalyst — management will present at the Guggenheim Emerging Outlook: Biotech Summit on Feb. 11; the presentation may supply pipeline updates or Q&A that could move the stock depending on tone and new details. Read More.
• Negative Sentiment: Insider and institutional selling produced near‑term downward pressure — Director Peter A. Thompson and Orbimed Advisors LLC disclosed sales of 29,063 shares (plus an additional 1,890-share trim) at ~ $44.57–$44.58. Although the sales represent small percentages of large holdings, they add liquidity and can prompt stop‑loss or momentum selling around those price levels. Read More. Read More.

Institutional Trading of Sionna Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new position in shares of Sionna Therapeutics during the 4th quarter valued at $36,000. Russell Investments Group Ltd. purchased a new position in shares of Sionna Therapeutics in the third quarter valued at about $30,000. BNP Paribas Financial Markets bought a new position in shares of Sionna Therapeutics in the second quarter worth about $31,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Sionna Therapeutics during the fourth quarter worth about $89,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in Sionna Therapeutics during the 2nd quarter valued at approximately $45,000.

Wall Street Analysts Forecast Growth

SION has been the subject of a number of recent research reports. Royal Bank Of Canada restated an “underperform” rating and set a $24.00 price target on shares of Sionna Therapeutics in a research note on Monday, December 1st. BTIG Research restated a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a research report on Wednesday, January 14th. Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Lifesci Capital initiated coverage on shares of Sionna Therapeutics in a research note on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 price target on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $45.43.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.